Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan NV    MYL   NL0011031208

MYLAN NV (MYL)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Mylan : Announces Voluntary Delisting from the Tel Aviv Stock Exchange (TASE)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:46pm CEST

HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv Stock Exchange (TASE). Under Israeli law, the delisting of Mylan's ordinary shares from the TASE will become effective in three months, on Feb. 12, 2018.

When Mylan first listed its shares on the TASE in November 2015, in connection with its attempt to acquire Perrigo, it committed to maintaining the listing for at least one year. Mylan has been listed on the TASE for more than two years.

Mylan's Chairman of the Board Robert J. Coury noted: "Over the last two years, we have learned that many of our Israeli institutional shareholders actually hold their shares in Mylan on the NASDAQ. Further, Mylan's holding on the TASE represents less than 3.5% of our total shareholdings and the average trading volume on the TASE is less than 3.5% of our global trading volume. Given these factors and the fact that the TASE's trading hours and days are different from other markets, our board of directors decided at this time that it would not be in Mylan's best interests to continue our listing on the TASE. That said, we do appreciate the ties we have forged with the Israeli institutional market."

Coury continued, "More importantly, over the last two years, I have had the privilege of becoming acquainted with the dynamic Israeli business environment and the strong work ethic of its people. As a result, we remain committed to considering future investments and other business development opportunities in Israel."

Mylan's shares will continue to be listed on the NASDAQ, and all of its ordinary shares now traded on the TASE may be transferred to the NASDAQ.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/mylan-announces-voluntary-delisting-from-the-tel-aviv-stock-exchange-tase-300553811.html

SOURCE Mylan N.V.


© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MYLAN NV
07/20MYLAN : Again Defeats Allergan's Efforts to Deny Patients Access to More Afforda..
PR
07/17ABBVIE : Signs Humira Patent License with Mylan
DJ
07/16Indivior's shares soar 33 percent after U.S. court blocks sale of rival gener..
RE
07/11Indivior warning on anti-opioid drug competition sends shares tumbling
RE
07/09MYLAN : Adds to Central Nervous System Portfolio With Launch of Generic Exelon® ..
PR
07/02Novartis Injects Itself Into Planned Rollout of EpiPen Competitor -- Update
DJ
07/02Complimentary Technical Snapshots on Mylan and Three More Generic Drugs Stock..
AC
07/02ADAMIS PHARMA : Novartis Unit to Obtain U.S. Rights to Potential EpiPen Rival Sy..
DJ
06/29Indivior gets breather after court extends order blocking generic rival
RE
06/28MYLAN STATEMENT : Morgantown Operations
PU
More news
News from SeekingAlpha
07/20Allergan strikes out with sovereign nation scheme to protect patents 
07/20FDA releases updated industry guidelines for development of generic abuse-det.. 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/17AbbVie out-licenses Humira patents to Mylan, biosimilar sales five years away.. 
07/16Mylan's cheap Copaxone to force Teva to discount - Bernstein